Heron Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Heron Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: For every $100 of sales, $112 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $96 tied up three years earlier. More money tied up than almost all Healthcare companies in United States.
- Cash Cushion Ratio: Debt, after subtracting cash, is 1.7 times its market value (net debt). Lower than 96% of Healthcare companies in United States.
- Growth Efficiency Ratio: Sales grew 44% in 3 years; of every extra $100 of sales, $343 became extra profit. Higher than 91% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-30.5×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 65% of Healthcare companies in United States.
Cash Locked Ratio
$112For every $100 of sales, $112 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $96 tied up three years earlier.
More money tied up than almost all Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$343Sales grew 44% in 3 years; of every extra $100 of sales, $343 became extra profit.
Higher than 91% of Healthcare companies in United States.
Asset Productivity Ratio
+44% / +2%In 3 years sales changed by +44% while total assets changed by +2%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
1.7× debtDebt, after subtracting cash, is 1.7 times its market value (net debt).
Lower than 96% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Heron Therapeutics, Inc. made a loss over the last year. Heron Therapeutics, Inc. owes $0.97 for every $1 it owns. Heron Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossHeron Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
8.14The share price is 8.14 times Heron Therapeutics, Inc.'s book value per share, higher than 83% of Healthcare companies in United States.
Market cap
$56 MThe total market value of all of Heron Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 72% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$7 MWhat Heron Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.04Net worth divided by the number of shares. The share price of $0.30 is 8.1 times this, which is the P/B above.
Owes vs Owns
0.97×Heron Therapeutics, Inc. owes $0.97 for every $1 it owns (high), higher than 86% of Healthcare companies in United States.
Dividend yield
NoneHeron Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
+7%Revenue rose 7% in the year to Dec 2025, and grew 13% a year on average over 3 years.
Profit growth
LossHeron Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-13.0%Heron Therapeutics, Inc. lost $13 for every $100 of revenue.
Interest cover
Not coveredHeron Therapeutics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debtHeron Therapeutics, Inc. had $94 M more debt than cash (net debt) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Heron Therapeutics, Inc.: $56 M ÷ $7 M (30 Jun 2026) = 8.1.
How much does Heron Therapeutics, Inc. owe compared with what it owns?
Heron Therapeutics, Inc. owes $0.97 for every $1 it owns (high), higher than 86% of Healthcare companies in United States.
Does Heron Therapeutics, Inc. pay a dividend?
No. Heron Therapeutics, Inc. does not currently pay a dividend.
Is Heron Therapeutics, Inc.'s revenue growing?
Revenue rose 7% in the year to Dec 2025, and grew 13% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.